Psoriatic arthritis

Bibliography

• O'NEILL TO, SILMAN AJ: Psoriatic Arthritis: Historicalbackground and epidemiology. Baillieres Rheumatol. (1994) 8:245–261.
   PubMed Web of Science ®Google Scholar
• MCGONAGLE D, CONAGHAN PG, EMERY P: Psoriaticarthritis: a unified concept twenty years on. Arthritis Rheum. (1999) 42:1080–1086.
   PubMed Web of Science ®Google Scholar
• SCARPA R, ORIENTE P, PUCINO A et al: The clinicalspectrum of psoriatic spondylitis. Br. J. Rheum. (1988) 27:133–137.
   PubMedGoogle Scholar
• BATTISTONE MJ, MANASTER BJ, REDA DJ, CLEGG DO:The prevalence of sacroiliitis in psoriatic arthritis: new perspectives from a large, multi-centre cohort. Skeletal Radio]. (1999) 28:196–201.
   PubMed Web of Science ®Google Scholar
• GLADMAN DD, BRUBACHER B, BUSKILA D, LANGEVITZP, FAREWELL VT: Differences in the expression of spondyloarthropathy: a comparison between ankylosing spondylitis and psoriatic arthritis. Genetic and gender effects. Clin. Invest. Med. (1993) 16:1–7.
   Google Scholar
• HELLIWELL PS, HICKLING P, WRIGHT V: Do theradiological changes of classic ankylosing spondylitis differ from the changes found in the spondylitis associated with inflammatory bowel disease, psoriasis and reactive arthritis? Ann. Rheum. Dis. (1998) 57:135–140.
   PubMed Web of Science ®Google Scholar
• MOLL JMH, WRIGHT V: Psoriatic arthritis. Seminars inArthritis and Rheumatism (1973) 3:55–78.
   PubMedGoogle Scholar
• BUSKILA D, LANGEVITZ P, GLADMAN DD, UROWITZ S,SMYTHE H: Patients with rheumatoid arthritis are more tender than those with psoriatic arthritis. J. Rheumatol. (1992) 19:1115–1119.
   PubMed Web of Science ®Google Scholar
• GLADMAN DD, SHUCKETT R, RUSSELL ML THORNE JC,SCHACHTER RK: Psoriatic arthritis - clinical and labora-tory analysis of 220 patients. Q. J. Med. (1987) 62:127–141.
   PubMedGoogle Scholar
• TORRE-ALONSO JC, RODRIGUES-PEREZ A, ARRIBAS-CASTRILLOM JM et al.: Psoriatic arthritis (PA): a clinical immunologic and radiological study. Br. J. Rheumatol (1991) 30:245–250.
   PubMedGoogle Scholar
• GLADMAN DD, FAREWELL VT, KOPCIUK K, COOK RJ: HLA antigens and progression in psoriatic arthritis. J. Rheumatol. (1998) 25:730–733.
   PubMed Web of Science ®Google Scholar
• GLADMAN DD, FAREWELL VT: Progression in psoriatic arthritis: Role of time varying clinical indicators. J. Rheumatol. (1999) 26:2409–2413.
   PubMed Web of Science ®Google Scholar
• WONG K, GLADMAN DD, HUSTED J, LONG JA, FAREWELLVT: Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum. (1997) 40:1868–1872.
   PubMed Web of Science ®Google Scholar
• GLADMAN DD, FAREWELL VT, HUSTED J, WONG K: Mortality studies in psoriatic arthritis. Results from a single centre. II. Prognostic indicators for mortality. Arthritis Rheum. (1998) 41:1103–1110.
   PubMed Web of Science ®Google Scholar
• MOLL JM, WRIGHT V: Familial occurrence of psoriaticarthritis. Ann. Rheum. Dis. (1973) 32:181–201.
   PubMed Web of Science ®Google Scholar
• LEDER RO, MANSBRIDGE JN, HALLMAYER J, HODGE SE:Familial psoriasis and HLA-B: Unambiguous support for linkage in 97 published families. Hum. Hered. (1998) 48:198–211.
   PubMed Web of Science ®Google Scholar
• GLADMAN DD, ANHORN KAB, SCHACHTER RK, MERVATH H: HLA antigens in psoriatic arthritis. J. Rheumatol. (1986) 13:586–592.
   PubMed Web of Science ®Google Scholar
• GLADMAN DD, CHEUNG C, NG CM, WADE JA: HLA C-locus alleles in psoriatic arthritis. Hum. Immunol (1999) 60:259–261.
   PubMed Web of Science ®Google Scholar
• OKA A, TAMIYA G, TMOZAWA M et al.: Association analysis using refined micro-satellite markers localizes a susceptibility locus for psoriasis vulgaris within a 111-kb segment telomeric of the HLA-C gene. Hum. Molec. Genet. (1999) 8:2165–2170.
   PubMed Web of Science ®Google Scholar
• WRONE-SMITH T, NICKOLOFF BJ: Dermal injection ofimmunocytes induces psoriasis. J. Clin. Invest. (1996) 98:1878–1887.
   PubMed Web of Science ®Google Scholar
• GLADMAN DD: The natural history of psoriaticarthritis. BailBeres Gun. Rheumatol. (1994) 8:379–394.
   PubMed Web of Science ®Google Scholar
• TASSIULAS I, DUNCAN SR, CENTOLA M, THEOFILO-POULOS AN, BOUMPAS DT: Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum. Immunol. (1999) 60:479–491.
   PubMed Web of Science ®Google Scholar
• MCGONAGLE D, GIBBON W, O'CONNOR P, GREEN M,PEASE C, EMERY P: Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondyloarthropathy. Arthritis Rheum. (1998) 41:694–701.
   PubMed Web of Science ®Google Scholar
• VEALE D, YANNI G, ROGERS S et al.: Reduced synovialmembrane macrophage numbers, ELAM1 expression and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum. (1993) 36:893–900.
   PubMed Web of Science ®Google Scholar
• RITCHLIN C, HAAS-SMITH SA, HICKS D, CAPPUCCIO J,OSTERLAND CK, LOONEY RJ: Patterns of cytokine production in psoriatic synovium. J. Rheumatol. (1998) 25:1544–1552.
   PubMed Web of Science ®Google Scholar
• TROUGHTON PR, MORGAN AW: Psoriatic arthritis: laboratory findings. Baillieres Clin. Rheumatol (1994) 8:439–463.
   PubMed Web of Science ®Google Scholar
• VINCENTI MP, CLARK IM, BICKERHOFF CE: Using inhibi-tors of metalloproteinases to treat arthritis. Arthritis Rheum. (1994) 37:1115–1126.
   PubMed Web of Science ®Google Scholar
• CUNNANE G, FITZGERALD O, HUMMEL KM, GAY RE, GAY S, BRESNIHAN B: Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early inflammatory arthritis. Rheumatology (1999) 38:34–42.
   PubMed Web of Science ®Google Scholar
• WANG Q, VASEY FB, MAHFOOD JP et al.: V2 regions of 16S ribosomal RNA used as a molecular marker for the species identification of streptococci in peripheral blood and synovial fluid from patients with psoriatic arthritis. Arthritis Rheum. (1999) 42:2055–2059.
   PubMed Web of Science ®Google Scholar
• ARNETT FC, REVEILLE JD, DUVIC M: Psoriasis andpsoriatic arthritis associated with human immunode-ficiency virus infection. Rheum. Dis. Clin. North Am. (1991) 17:59–78.
   PubMed Web of Science ®Google Scholar
• REVEILLE JD, CONANT MA, DUVIC M: Human immuno-deficiency virus-associated psoriasis, psoriatic arthritis and Reiter's syndrome: a disease continuum? Arthritis Rheum. (1990) 33:1574–1578.
   Google Scholar
• PUNZI L, PIANON M, BERTAZZOLO N et al.: Clinical,laboratory and immunogenetic aspects of post-traumatic psoriatic arthritis: a study of 25 patients. Clin. Exp. Rheumatol. (1998) 16:277–281.
   PubMed Web of Science ®Google Scholar
• BRUCE I, GLADMAN DD: Psoriatic arthritis: recognition and management. Biodrugs (1998) 9:271–278.
   PubMed Web of Science ®Google Scholar
• GLADMAN DD, STAFFORD-BRADY F, CHANG CH, LEWANDOWSKI K, RUSSELL ML: Longitudinal study of clinical and radiological progression in psoriatic arthritis. J. Rheumatol. (1990) 17:809–812.
   PubMed Web of Science ®Google Scholar
• JONES G, CROTTY M, BROOKS P et al.: Psoriatic arthritis: a quantitative overview of therapeutic options. Br. J. Rheumatol. (1997) 36:95–99.
   PubMedGoogle Scholar
• BLACK RL, O'BRIEN WM, VAN SCOTT EJ, AUERBACH R, EISEN AZ, BUNIM JJ: Methotrexate therapy in psoriatic arthritis. Double blind study on 21 patients. JAMA (1964) 189:743–747.
   Google Scholar
• WILKENS RF, WILLIAMS J, WARD JR et al.: Randomized double blind, placebo-controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum. (1984) 27:376–381.
   PubMed Web of Science ®Google Scholar
• ZACHARIAS H, ZACHARIAS E: Methotrexate treatment of psoriatic arthritis. Acta Derm. Venereol (1987) 67:270–273.
   PubMed Web of Science ®Google Scholar
• ESPINOZA LR, ZAKRAONI L ESPINOZA CG et al.: Psoriaticarthritis: clinical response and side effects of methotrexate therapy. J. Rheumatol. (1992) 19:872–877.
   Google Scholar
• ABU-SHAKRA M, GLADMAN DD, THORNE JC et al.: Long-term methotrexate therapy in psoriatic arthritis: clinical and radiologic outcome. J. Rheumatol (1995) 22:241–245.
   PubMed Web of Science ®Google Scholar
• STEINSSON K, JONSDOTTIR I, VALDIMARSSON H: Cyclosporin A in psoriatic arthritis: an open study. Ann. Rheum. Dis. (1990) 49:603–606.
   PubMed Web of Science ®Google Scholar
• SPADARAO A, RICCIERI V, SILI-SCAVALLI A et al.: Comparison of cyclosporin A and Methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin. Exp. Rheumatol. (1995) 13:589–593.
   PubMed Web of Science ®Google Scholar
• CLEGG DO, REDA DJ, MEJIAS E et al.: Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Coopera-tive Study. Arthritis Rheum. (1996) 39:2013–2020.
   PubMed Web of Science ®Google Scholar
• COMBE B, GOUPILLE P, KUNTZ JL, TEBIB J, LIOTE F, BREGEON C: Sulphasalazine in psoriatic arthritis: a randomized, multi-centre, placebo-controlled study. Br. J. Rheumatol. (1996) 35:664–668.
   PubMedGoogle Scholar
• RAHMAN, P, GLADMAN, DD, ZHOU, Y, COOK, RJ: The use of sulfasalazine in psoriatic arthritis: a clinic experi-ence. J. Rheumatol. (1998) 25:1957–1961.
   PubMed Web of Science ®Google Scholar
• PALIT J, HILL J, CAPELL HA et al.: A multi-centre double-blind comparison of auranofin, intra-muscular gold thiomalate and placebo in patients with psoriatic arthritis. Br. J. Rheumatol. (1990) 29:280–283.
   PubMedGoogle Scholar
• MADER R, GLADMAN DD, LONG J GOUGH J, FAREWELL VT: Injectable gold for the treatment of psoriatic arthritis (PsA) - long-term follow up. Clin. Invest. Med. (1995) 18:139–143.
   PubMed Web of Science ®Google Scholar
• GLADMAN DD, BLAKE R, BRUBACHER B, FAREWELL VT: Chloroquine therapy in psoriatic arthritis. J. Rheumatol. (1992) 19:1724-1726. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (2000) 9(7)
   Google Scholar
• KIRWAN JR: The effect of glucocorticoids on jointdestruction in rheumatoid arthritis. The Arthritis and Rheumatism Council low-dose glucocorticoid study group. N Engl. J. Med. (1995) 333:142–146.
   Google Scholar
• KAY L, WALKER D: Therapy for psoriatic arthritis:Sometimes a conflict for psoriasis. Br. J. Rheumatol. (1998) 37:234–235.
   PubMedGoogle Scholar
• KLINKHOFF AV, GERTNER E, CHALMERS A et al: Pilotstudy of etretinate in psoriatic arthritis. J. Rheumatol (1989) 16:789–791.
   PubMed Web of Science ®Google Scholar
• PERLMAN SG, GERBER LH, ROBERTS M et al: Photoche-motherapy and psoriatic arthritis. A prospective study. Ann. Int. Med. (1979) 91:717–722.
   PubMed Web of Science ®Google Scholar
• ELLIOTT MJ, MAINI RN, FELDMANN M et al: Randomiseddouble-blind comparison of chimeric monoclonal antibody to tumour necrosis factor-a (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 344:1105–1110.
   PubMed Web of Science ®Google Scholar
• MAINI RN, BREEDVELD FC, KALDEN JR et al.: Therapeuticefficacy of multiple intravenous infusions of anti-tumour necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in Rheumatoid Arthritis. Arthritis Rheum. (1998) 41:1552–1563.
   PubMed Web of Science ®Google Scholar
• MORELAND LW, SCHIFF MH, BAUMGARTNER SW et al:Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl. J. Med. (1997) 33 7 :141–147.
   Web of Science ®Google Scholar
• WEINBLATT ME, KREMER JM, BANKHURST AD et al.: Atrial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl. J. Med. (1999) 340:253–259.
   PubMed Web of Science ®Google Scholar
• FINCK B, MARTIN R, FLEISCHMANN R, MORELAND L, SCHIFF M, BATHON J: A phase iii trial of etanercept vs. methotrexate (MTX) in early rheumatoid arthritis (ENBREL® ERA trial). Arthritis Rheum. (1999) 42:S.
   Google Scholar
• PARTSCH G, STEINER G, LEEB BF et al: Highly increased levels of tumor necrosis factor-a and other pro-inflammatory cytokines in psoriatic arthritis synovial fluid. J. Rheumatol (1997) 24:518–523.
   PubMed Web of Science ®Google Scholar
• PARTSCH G, WAGNER E, LEEB BF et al: Up-regulation of cytokine receptors sTNF-R55, sTNF-R75 and sIL-2R in psoriatic arthritis synovial fluid. J. Rheumatol. (1998) 25:105–110.
   PubMed Web of Science ®Google Scholar
• HOHLER T, KRUGER A, SCHNEIDER PM: A TNF-a promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J. Invest. Dermatol. (1997) 109:562–565.
   PubMed Web of Science ®Google Scholar
• MEASE P, GOFFE B, METZ J: Enbrel (etanercept) inpatients with psoriatic arthritis and psoriasis. Arthritis Rheum. (1999) 42 (Suppl. 9):S377.
   Google Scholar
• YAZICI Y, ERKAN D, LOCKSHIN MD: Etanercept in thetreatment of severe resistant psoriatic arthritis. Arthritis Rheum. (1999) 42 (Suppl. 9):S379.
   Google Scholar
• ANTONI C, DECHANT C, LORENZ H et al.: Successfultreatment of severe psoriatic arthritis with infliximab. Arthritis Rheum. (1999) 42 (Suppl. 9):S371.
   Google Scholar
• BRESNIHAN B, ALVARO-GRACIA JM,COBBY M et al.: Treatment of Rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. (1998) 41:2196–2204.
   Google Scholar
• BUTLER DM, MALFAIT AM, MAINI RN, BRENNAN FM, FELDMANN M: Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis. Eur. J. Immunol. (1999) 29:2205–2212.
   PubMed Web of Science ®Google Scholar
• BREEDVALD FC: Future trends in the treatment ofrheumatoid arthritis: cytokine targets. Rheumatology (1999) 38 (Suppl. 2):11–13.
   Google Scholar
• MCINNES IB, ILLEI GG, DANNING CL et al.: Profoundimmunomodulatory effects of IL-10 administration in psoriatic arthritis patients. Arthritis Rheum. (1999) 42 (Suppl. 9):S376.
   Google Scholar
• ASADULLAH K, DOCKE WD, EBELING M: Interleukin 10treatment of psoriasis: clinical results of a Phase 2 trial. Br. J. Dermatol (1999) 135:187–192.
   Google Scholar
• WENDLING D, RACADOT E, WIJDENES J et al: A random-ized, double blind, placebo controlled multi-center trial of murine anti-CD4 monoclonal antibody therapy in rheumatoid arthritis. J. Rheumatol. (1998) 25 :1457–1461.
   PubMed Web of Science ®Google Scholar
• COSTELLO P. BRESNIHAN B. O'FARRELLY C. FITZGERALD0: Predominance of CD8+ T lymphocytes in psoriatic arthritis. J. Rheumatol. (1999) 26:1117–1124.
   PubMed Web of Science ®Google Scholar
• BACHELEZ H, FLAGUEL B, DUBERTRET L et al.:Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4. J. Autoimmun. (1998) 11:53–62.
   PubMed Web of Science ®Google Scholar
• KIELY PD, O'BRIEN D, OLIVEIRA DB: Anti-CD8 treatmentreduces the severity of inflammatory arthritis, but not vasculitis, in mercuric chloride-induced autoimmu-nity. Clin. Exp. Immunol. (1996) 106:280–285.
   PubMed Web of Science ®Google Scholar
• YOCUM DE: T Cells: pathogenic cells and therapeutictargets in rheumatoid arthritis. Semin. Arthritis Rheum. 29:27–35.
   Google Scholar
• SMOLEN JS, KALDEN JR, SCOTT DL et al.: Efficacy andsafety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double blind, randomised, multicentre trial. Lancet (1999) 353:259–266.
   PubMed Web of Science ®Google Scholar
• SCHIFF M, SHARP J, SMOLEN J et al.: Consistency ofleflunomide effect for slowing the radiographic disease progression of active rheumatoid arthritis: results from three controlled trials. Arthritis Rheum. (1999) 42 (Suppl. 9):581.
   Google Scholar
• LIANG GC, BARR WG:Leflunomide for psorsiasis andpsoriatic arthritis. Arthritis Rheum. (1999) 42 (Suppl. 9):S1515.
   Google Scholar
• FURST DE: Leflunomide, mycophenolic acid and matrix metalloproteinase inhibitors. Rheumatology (1999) 38 (Suppl. 2):14–18.
   Google Scholar
• HAUFS MG, BEISSERT S, GRABBE S, SCHUTTE B, LUGERTA: Psoriasis vulgaris treated successfully with mycophenolate mofetil. Br. J. Dermatol. (1998) 138:79–81.
   Web of Science ®Google Scholar
• SCHIFF M, STEIN G, LEISCHMAN B: Cellcept (mycophe-nolate mofetil - MMF) a new treatment for RA: a 9-month, randomized, double blind trial comparing lg bid and 2g bid. Arthritis Rheum. (1997) 40 (Suppl. 9):S194.
   Google Scholar
• ABRAMS JR, LEBWOHL MG, GUZZO CA et al.: CTLA4Ig-mediated blockade of T-cell co-stimulation in patients with psoriasis vulgaris. j Olin. Invest. (1999) 9:1243–1252.
   Web of Science ®Google Scholar
• KAVANAUGH AF, SCHULZE-KOOPS H, DAVIS LS, LIPSKY PE: Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody. Arthritis Rheum. (1997) 40:849–853.
   PubMed Web of Science ®Google Scholar
• DAVIS JC JR, FESSLER BJ, TASSIULAS 10 et al.: High dose versus low dose fludarabine in the treatment of patients with severe refractory rheumatoid arthritis. J. Rheumatol. (1998) 25:1694–1704.
   Google Scholar
• KARADOGAN I, AKCA S, UNDAR L: Resolution of psoriatic skin lesions with fludarabine. Am. J. Med. (1999) 107:300–301.
   PubMed Web of Science ®Google Scholar
• O'DELL JR, HAIRE CE, PALMER W et al.: Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double blind, placebo-controlled trial. Arthritis Rheum. (1997) 40:842–848.
   Google Scholar
• O'DELL JR, PAULSEN G, HAIRE CE: Treatment of earlyseropositive rheumatoid arthritis with minocycline: four-year follow-up of a double blind, placebo-controlled trial. Arthritis Rheum. (1999) 42:1691–1695.
   PubMed Web of Science ®Google Scholar
• BLUHM GB, SHARP JT, TILLEY BC: Radiographic results from the Minocycline in Rheumatoid Arthritis (MIRA) Trial. J. Rheumatol. (1997) 24:1295–1302.
   PubMed Web of Science ®Google Scholar
• CHOY EH: New Prospects for the treatment of rheuma-toid arthritis. Exp. Opin. Invest. Drugs (1998) 7:1087–1097.
   PubMedGoogle Scholar
• AMOR B, DOUGADOS M, MIJIJAWA M: Criteres de classi-fication des spondylarthropathies. Rev. Rhum. (1990) 57:85–89.
   PubMedGoogle Scholar
• CLEGG DO, REDA DJ, WEISMAN MH: Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. (1996) 39:2004–2012.
   PubMed Web of Science ®Google Scholar
• CLEGG DO, REDA DJ, ABDELLATIF M: Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum. (1999) 42:2325–2329.
   PubMed Web of Science ®Google Scholar
• MAKSYMOWYCH WP, JHANGRI GS, LECLERCQ S, SKEITH K, YAN A, RUSSELL AS: An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J. Rheumatol (1998) 25:714–717.
   PubMed Web of Science ®Google Scholar
• MAKSYMOWYCH WP, LECLERCQ S, JHANGRI GS: A randomized double-blind dose response comparison of intravenous pamidronate in the treatment of NSAID-refractory ankylosing spondylitis. Arthritis Rheum. (1999) 42 (Suppl. 9):S376.
   Google Scholar